A small-molecule TREM2 agonist for Alzheimer’s disease
Nature Medicine, Published online: 29 October 2026; doi:10.1038/d41591-026-00055-x Preclinical analysis and a phase 1 trial support VG-3927 as a promising drug candidate for Alzheimer’s disease, demonstrating successful penetration of the central nervous system, target engagement and tolerability.
We haven't written up this one. Nature Medicine has the full story — the link below goes straight to it.